Vera Therapeutics (VERA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Vera Therapeutics (VERA) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +1.00 of bullish evidence against -0.25 bearish.

Vera Therapeutics last closed at $29.83, -1.94% on the session.

Against the IVW growth benchmark the position is -2.86% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

7 graded predictions for VERA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Vera Therapeutics in the 13th percentile on return on equity, where 100 is best.

Vera Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $2.19B.

StockMap tracks Vera Therapeutics as the 78th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Vera Therapeutics ranks 209th of 344 in the group, against a group median of -0.21.